Secretogranin III

a diabetic retinopathy-selective angiogenic factor

Wei Li, Keith A Webster, Michelle E. LeBlanc, Hong Tian

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Secretogranin III (Scg3) is a member of the granin protein family that regulates the biogenesis of secretory granules. Scg3 was recently discovered as an angiogenic factor, expanding its functional role to extrinsic regulation. Unlike many other known angiogenic factors, the pro-angiogenic actions of Scg3 are restricted to pathological conditions. Among thousands of quantified endothelial ligands, Scg3 has the highest binding activity ratio to diabetic vs. healthy mouse retinas and lowest background binding to normal vessels. In contrast, vascular endothelial growth factor binds to and stimulates angiogenesis of both diabetic and control vasculature. Consistent with its role in pathological angiogenesis, Scg3-neutralizing antibodies alleviate retinal vascular leakage in mouse models of diabetic retinopathy and retinal neovascularization in oxygen-induced retinopathy mice. This review summarizes our current knowledge of Scg3 as a regulatory protein of secretory granules, highlights its new role as a highly disease-selective angiogenic factor, and envisions Scg3 inhibitors as “selective angiogenesis blockers” for targeted therapy.

Original languageEnglish (US)
Pages (from-to)635-647
Number of pages13
JournalCellular and Molecular Life Sciences
Volume75
Issue number4
DOIs
StatePublished - Feb 1 2018

Fingerprint

Angiogenesis Inducing Agents
Diabetic Retinopathy
Secretory Vesicles
Pathologic Neovascularization
Retinal Neovascularization
Chromogranins
Retinal Vessels
Neutralizing Antibodies
Vascular Endothelial Growth Factor A
Retina
Proteins
Oxygen
Ligands
secretogranin III
Therapeutics

Keywords

  • Anti-angiogenesis therapy
  • Comparative ligandomics
  • Diabetic macular edema
  • Ligandomics
  • Proliferative diabetic retinopathy
  • Retinopathy of prematurity

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Pharmacology
  • Cellular and Molecular Neuroscience
  • Cell Biology

Cite this

Secretogranin III : a diabetic retinopathy-selective angiogenic factor. / Li, Wei; Webster, Keith A; LeBlanc, Michelle E.; Tian, Hong.

In: Cellular and Molecular Life Sciences, Vol. 75, No. 4, 01.02.2018, p. 635-647.

Research output: Contribution to journalReview article

Li, Wei ; Webster, Keith A ; LeBlanc, Michelle E. ; Tian, Hong. / Secretogranin III : a diabetic retinopathy-selective angiogenic factor. In: Cellular and Molecular Life Sciences. 2018 ; Vol. 75, No. 4. pp. 635-647.
@article{2d0de9045abb48ee86bea8cf78222e6f,
title = "Secretogranin III: a diabetic retinopathy-selective angiogenic factor",
abstract = "Secretogranin III (Scg3) is a member of the granin protein family that regulates the biogenesis of secretory granules. Scg3 was recently discovered as an angiogenic factor, expanding its functional role to extrinsic regulation. Unlike many other known angiogenic factors, the pro-angiogenic actions of Scg3 are restricted to pathological conditions. Among thousands of quantified endothelial ligands, Scg3 has the highest binding activity ratio to diabetic vs. healthy mouse retinas and lowest background binding to normal vessels. In contrast, vascular endothelial growth factor binds to and stimulates angiogenesis of both diabetic and control vasculature. Consistent with its role in pathological angiogenesis, Scg3-neutralizing antibodies alleviate retinal vascular leakage in mouse models of diabetic retinopathy and retinal neovascularization in oxygen-induced retinopathy mice. This review summarizes our current knowledge of Scg3 as a regulatory protein of secretory granules, highlights its new role as a highly disease-selective angiogenic factor, and envisions Scg3 inhibitors as “selective angiogenesis blockers” for targeted therapy.",
keywords = "Anti-angiogenesis therapy, Comparative ligandomics, Diabetic macular edema, Ligandomics, Proliferative diabetic retinopathy, Retinopathy of prematurity",
author = "Wei Li and Webster, {Keith A} and LeBlanc, {Michelle E.} and Hong Tian",
year = "2018",
month = "2",
day = "1",
doi = "10.1007/s00018-017-2635-5",
language = "English (US)",
volume = "75",
pages = "635--647",
journal = "Cellular and Molecular Life Sciences",
issn = "1420-682X",
publisher = "Birkhauser Verlag Basel",
number = "4",

}

TY - JOUR

T1 - Secretogranin III

T2 - a diabetic retinopathy-selective angiogenic factor

AU - Li, Wei

AU - Webster, Keith A

AU - LeBlanc, Michelle E.

AU - Tian, Hong

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Secretogranin III (Scg3) is a member of the granin protein family that regulates the biogenesis of secretory granules. Scg3 was recently discovered as an angiogenic factor, expanding its functional role to extrinsic regulation. Unlike many other known angiogenic factors, the pro-angiogenic actions of Scg3 are restricted to pathological conditions. Among thousands of quantified endothelial ligands, Scg3 has the highest binding activity ratio to diabetic vs. healthy mouse retinas and lowest background binding to normal vessels. In contrast, vascular endothelial growth factor binds to and stimulates angiogenesis of both diabetic and control vasculature. Consistent with its role in pathological angiogenesis, Scg3-neutralizing antibodies alleviate retinal vascular leakage in mouse models of diabetic retinopathy and retinal neovascularization in oxygen-induced retinopathy mice. This review summarizes our current knowledge of Scg3 as a regulatory protein of secretory granules, highlights its new role as a highly disease-selective angiogenic factor, and envisions Scg3 inhibitors as “selective angiogenesis blockers” for targeted therapy.

AB - Secretogranin III (Scg3) is a member of the granin protein family that regulates the biogenesis of secretory granules. Scg3 was recently discovered as an angiogenic factor, expanding its functional role to extrinsic regulation. Unlike many other known angiogenic factors, the pro-angiogenic actions of Scg3 are restricted to pathological conditions. Among thousands of quantified endothelial ligands, Scg3 has the highest binding activity ratio to diabetic vs. healthy mouse retinas and lowest background binding to normal vessels. In contrast, vascular endothelial growth factor binds to and stimulates angiogenesis of both diabetic and control vasculature. Consistent with its role in pathological angiogenesis, Scg3-neutralizing antibodies alleviate retinal vascular leakage in mouse models of diabetic retinopathy and retinal neovascularization in oxygen-induced retinopathy mice. This review summarizes our current knowledge of Scg3 as a regulatory protein of secretory granules, highlights its new role as a highly disease-selective angiogenic factor, and envisions Scg3 inhibitors as “selective angiogenesis blockers” for targeted therapy.

KW - Anti-angiogenesis therapy

KW - Comparative ligandomics

KW - Diabetic macular edema

KW - Ligandomics

KW - Proliferative diabetic retinopathy

KW - Retinopathy of prematurity

UR - http://www.scopus.com/inward/record.url?scp=85045289392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045289392&partnerID=8YFLogxK

U2 - 10.1007/s00018-017-2635-5

DO - 10.1007/s00018-017-2635-5

M3 - Review article

VL - 75

SP - 635

EP - 647

JO - Cellular and Molecular Life Sciences

JF - Cellular and Molecular Life Sciences

SN - 1420-682X

IS - 4

ER -